NCT06895538View on ClinicalTrials.gov

Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy

RecruitingOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

May 3, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
LeukemiaMDSLymphoma
Interventions
DRUG

Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)

Patients in the ATLG arm receive ATLG instead of ATG as part of the routine conditioning regimen before allo-HSCT; ATLG is given intravenously by infusion for 4 consecutive days, after which they undergo routine transplantation.

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER